164 related articles for article (PubMed ID: 19456253)
1. Targeted treatment of choroidal neovascularization using integrin-mediated sterically stabilized liposomes loaded with combretastatin A4.
Ma L; Liu YL; Ma ZZ; Dou HL; Xu JH; Wang JC; Zhang X; Zhang Q
J Ocul Pharmacol Ther; 2009 Jun; 25(3):195-200. PubMed ID: 19456253
[TBL] [Abstract][Full Text] [Related]
2. A tumor vasculature targeted liposome delivery system for combretastatin A4: design, characterization, and in vitro evaluation.
Nallamothu R; Wood GC; Pattillo CB; Scott RC; Kiani MF; Moore BM; Thoma LA
AAPS PharmSciTech; 2006 Apr; 7(2):E32. PubMed ID: 16796350
[TBL] [Abstract][Full Text] [Related]
3. Targeted polymeric micelle system for delivery of combretastatin A4 to tumor vasculature in vitro.
Wang Y; Yang T; Wang X; Wang J; Zhang X; Zhang Q
Pharm Res; 2010 Sep; 27(9):1861-8. PubMed ID: 20559700
[TBL] [Abstract][Full Text] [Related]
4. A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies.
Nallamothu R; Wood GC; Kiani MF; Moore BM; Horton FP; Thoma LA
PDA J Pharm Sci Technol; 2006; 60(3):144-55. PubMed ID: 17089683
[TBL] [Abstract][Full Text] [Related]
5. Combination of targeted PDT and anti-VEGF therapy for rat CNV by RGD-modified liposomal photocyanine and sorafenib.
Wang JL; Xi Y; Liu YL; Wang ZH; Zhang Q
Invest Ophthalmol Vis Sci; 2013 Dec; 54(13):7983-9. PubMed ID: 24204046
[TBL] [Abstract][Full Text] [Related]
6. EphA2 targeted doxorubicin stealth liposomes as a therapy system for choroidal neovascularization in rats.
Wang JL; Liu YL; Li Y; Dai WB; Guo ZM; Wang ZH; Zhang Q
Invest Ophthalmol Vis Sci; 2012 Oct; 53(11):7348-57. PubMed ID: 22977140
[TBL] [Abstract][Full Text] [Related]
7. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo.
Xiong XB; Huang Y; Lu WL; Zhang X; Zhang H; Nagai T; Zhang Q
J Pharm Sci; 2005 Aug; 94(8):1782-93. PubMed ID: 15986461
[TBL] [Abstract][Full Text] [Related]
8. [Cellular toxicity and anti-tumor efficacy of iRGD modified doxorubixin loaded sterically stabilized liposomes].
Zhao B; Fan YC; Wang XQ; Dai WB; Zhang Q; Wang XL
Yao Xue Xue Bao; 2013 Mar; 48(3):417-22. PubMed ID: 23724658
[TBL] [Abstract][Full Text] [Related]
9. Multi-targeting NGR-modified liposomes recognizing glioma tumor cells and vasculogenic mimicry for improving anti-glioma therapy.
Huang D; Zhang S; Zhong T; Ren W; Yao X; Guo Y; Duan XC; Yin YF; Zhang SS; Zhang X
Oncotarget; 2016 Jul; 7(28):43616-43628. PubMed ID: 27283987
[TBL] [Abstract][Full Text] [Related]
10. Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo.
Xiong XB; Huang Y; Lu WL; Zhang H; Zhang X; Zhang Q
Pharm Res; 2005 Jun; 22(6):933-9. PubMed ID: 15948037
[TBL] [Abstract][Full Text] [Related]
11. Topical ocular delivery to laser-induced choroidal neovascularization by dual internalizing RGD and TAT peptide-modified nanoparticles.
Chu Y; Chen N; Yu H; Mu H; He B; Hua H; Wang A; Sun K
Int J Nanomedicine; 2017; 12():1353-1368. PubMed ID: 28260884
[TBL] [Abstract][Full Text] [Related]
12. RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer.
Zhao H; Wang JC; Sun QS; Luo CL; Zhang Q
J Drug Target; 2009 Jan; 17(1):10-8. PubMed ID: 19016068
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel.
Luo LM; Huang Y; Zhao BX; Zhao X; Duan Y; Du R; Yu KF; Song P; Zhao Y; Zhang X; Zhang Q
Biomaterials; 2013 Jan; 34(4):1102-14. PubMed ID: 23127332
[TBL] [Abstract][Full Text] [Related]
14. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic.
Xiong XB; Huang Y; Lu WL; Zhang X; Zhang H; Nagai T; Zhang Q
J Control Release; 2005 Oct; 107(2):262-75. PubMed ID: 16125816
[TBL] [Abstract][Full Text] [Related]
15. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
[TBL] [Abstract][Full Text] [Related]
16. Suppression of choroidal neovascularization by intravitreal injection of liposomal SU5416.
Honda M; Asai T; Umemoto T; Araki Y; Oku N; Tanaka M
Arch Ophthalmol; 2011 Mar; 129(3):317-21. PubMed ID: 21402988
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody-mediated drug targeting to choroidal neovascularization in the rat.
Kamizuru H; Kimura H; Yasukawa T; Tabata Y; Honda Y; Ogura Y
Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2664-72. PubMed ID: 11581214
[TBL] [Abstract][Full Text] [Related]
18. Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery.
Kibria G; Hatakeyama H; Ohga N; Hida K; Harashima H
J Control Release; 2011 Jul; 153(2):141-8. PubMed ID: 21447361
[TBL] [Abstract][Full Text] [Related]
19. RGD-modified polymeric micelles as potential carriers for targeted delivery to integrin-overexpressing tumor vasculature and tumor cells.
Wang Y; Wang X; Zhang Y; Yang S; Wang J; Zhang X; Zhang Q
J Drug Target; 2009 Jul; 17(6):459-67. PubMed ID: 19527117
[TBL] [Abstract][Full Text] [Related]
20. A lipid nanoparticle system improves siRNA efficacy in RPE cells and a laser-induced murine CNV model.
Liu HA; Liu YL; Ma ZZ; Wang JC; Zhang Q
Invest Ophthalmol Vis Sci; 2011 Jul; 52(7):4789-94. PubMed ID: 21519028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
